Buying a Vagus Nerve Stimulator: What to Know Before You Spend

The vagus nerve stimulation device market has expanded rapidly from a single implantable system to a landscape of prescription devices, FDA-cleared non-invasive units, and consumer-grade products of widely varying quality. If you are considering purchasing a vagus nerve stimulator, the most important thing to understand upfront is this: these devices range from rigorously tested medical devices backed by randomised controlled trials to consumer gadgets with no clinical evidence whatsoever. Knowing which category a device falls into — and what it can realistically do for you — will save you from spending hundreds or thousands of dollars on something that may not work.

Implantable VNS: The Medical-Grade Standard

Implantable vagus nerve stimulation (iVNS) remains the gold standard for clinical VNS. The LivaNova VNS Therapy system (formerly Cyberonics) has been FDA-approved for drug-resistant epilepsy since 1997 and for treatment-resistant depression since 2005. A pulse generator roughly the size of a silver dollar is surgically implanted in the left chest wall, with a lead wire wrapped around the left cervical vagus nerve. The device delivers programmed electrical pulses — typically 30 seconds on, 5 minutes off — continuously, 24 hours a day.

This is not something you “buy” in the consumer sense. It requires a neurosurgeon or epileptologist referral, surgical implantation under general anaesthesia, and ongoing programming by a neurologist. The device itself costs $20,000–$40,000 before surgical fees, and is typically covered by insurance for FDA-approved indications. Battery life is 3–8 years depending on stimulation settings, after which the generator must be surgically replaced (the lead usually stays in place).

For drug-resistant epilepsy, long-term data show that approximately 50% of patients experience a 50% or greater reduction in seizure frequency, with efficacy improving over the first 1–2 years of use. For treatment-resistant depression, the evidence is more mixed — the pivotal randomised trial failed its primary endpoint, though open-label registry data and the long-term RESTORE study suggest sustained benefit in a subset of patients. iVNS is not a consumer product and is not discussed further in this buying guide — but it is important context, because it is the benchmark against which all other devices should be measured.

Prescription Non-Invasive Devices

gammaCore (electroCore) is an FDA-cleared handheld device that stimulates the cervical vagus nerve through the skin of the neck. It is cleared for acute treatment and prevention of episodic cluster headache, acute treatment of migraine, and (as of 2024) paroxysmal supraventricular tachycardia. The user places two stainless steel electrodes against the neck over the vagus nerve and delivers 2-minute stimulation cycles.

gammaCore requires a prescription in the United States, though it was reclassified in 2024 to allow broader access. Pricing is approximately $600 for a unit pre-loaded with a set number of stimulations, with ongoing costs for refills or new units. The clinical evidence base is substantial — multiple RCTs support its efficacy for cluster headache (the ACT1 and ACT2 trials) and migraine (the PRESTO and PREMIUM trials), though effect sizes are moderate. It is not FDA-cleared for depression, anxiety, or general “vagal toning.”

NEMOS (tVNS Technologies / cerbomed) is a transcutaneous auricular VNS (taVNS) device developed in Germany that stimulates the auricular branch of the vagus nerve (Arnold’s nerve) at the cymba conchae of the ear via a custom ear electrode. It carries CE marking in Europe for epilepsy and depression but is not FDA-cleared in the US. The evidence base includes several small to medium RCTs — the randomised study by Bauer et al. (2016) in Epilepsia showed a 34% responder rate in drug-resistant epilepsy using 1 Hz stimulation over 20 weeks, though this did not reach statistical significance against the active control group.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

Consumer taVNS Devices

The fastest-growing segment is consumer transcutaneous auricular VNS devices. These typically stimulate the ear (cymba conchae, tragus, or both) and are sold directly to consumers without a prescription, usually classified as general wellness devices rather than medical devices. This classification means they have not undergone FDA review for safety or efficacy for any medical condition — they cannot legally make disease-treatment claims, though marketing often implies therapeutic benefit.

What to evaluate in any consumer taVNS device:

Stimulation target. The cymba conchae has the densest innervation by Arnold’s nerve (the auricular branch of the vagus), as demonstrated by Peuker and Filler’s 2002 anatomical study. The tragus has mixed innervation (Arnold’s nerve plus the auriculotemporal nerve from the trigeminal). The earlobe has no vagal innervation — it is supplied by the great auricular nerve (C2–C3). Any device stimulating the earlobe is not performing vagus nerve stimulation, regardless of its marketing. Check where the electrodes actually make contact.

Stimulation parameters. The most commonly studied parameters in taVNS research are: frequency of 25 Hz (most common in clinical trials, though 1 Hz has also been studied for epilepsy), pulse width of 200–300 microseconds, and current intensity adjusted to individual sensory threshold (typically 0.5–5 mA). Devices that do not disclose their stimulation parameters, or use parameters far outside the researched ranges, should be treated with scepticism.

Electrode quality and ear fit. Good skin-electrode contact is essential for consistent current delivery. Custom-moulded ear electrodes (like NEMOS) provide the best contact but are expensive. Clip-on electrodes are more practical for consumer use but vary widely in contact quality. Dry electrodes require higher voltage to overcome skin impedance; gel or saline-wetted electrodes provide better conductivity at lower voltages.

Adjustable intensity. Current intensity should be user-adjustable, ideally in small increments (0.1–0.25 mA steps). The target is typically “strong but comfortable” — above sensory threshold but below pain threshold. A device with only fixed intensity settings cannot accommodate individual variation in skin impedance and sensory threshold.

Session timing. Most clinical taVNS protocols use 30–60 minute sessions, once or twice daily. Some consumer devices use shorter sessions (15–20 minutes). Devices claiming benefits from 5-minute sessions have no clinical evidence supporting such brief stimulation durations.

Red Flags When Shopping

The vagus nerve stimulator market is plagued by overclaiming. Be cautious of any device that claims to treat specific medical conditions (epilepsy, depression, PTSD, autoimmune disease) without FDA clearance for those indications — this is illegal under US law, regardless of whether the device actually stimulates the vagus nerve. Claims of “FDA-approved” when the device is only “FDA-registered” (which means almost nothing — registration is a notification to the FDA, not an approval or clearance) should raise immediate concern.

Devices marketed as vagus nerve stimulators that deliver stimulation through the wrist, behind the ear (mastoid), or to the earlobe are not stimulating the vagus nerve, based on established neuroanatomy. TENS (transcutaneous electrical nerve stimulation) units repurposed and rebranded as “vagus nerve stimulators” may deliver electrical stimulation but are not designed for auricular or cervical vagal targets and lack the precision electrode design needed for consistent vagal nerve activation.

Price alone is not a reliable indicator of quality. Consumer taVNS devices range from $50 to $700+. A higher price does not guarantee better stimulation parameters, electrode design, or clinical evidence. Conversely, extremely cheap devices (under $30) are unlikely to have the precision electronics needed for consistent current delivery across varying skin impedances.

A Realistic Expectation Framework

For FDA-cleared prescription devices (gammaCore), expectations should be anchored to their clinical trial results — moderate efficacy for their cleared indications, with individual response varying. For consumer taVNS devices, the honest answer is that you are using a device whose specific configuration has almost certainly not been tested in any clinical trial, and whose effects — if any — are likely modest and variable. The underlying concept is sound (auricular vagus nerve stimulation does activate vagal pathways, as demonstrated by fMRI studies showing NTS activation during cymba conchae stimulation), but the gap between “the concept has scientific support” and “this particular $200 device will improve your specific condition” is large.

Consumer taVNS is most reasonably approached as a low-risk complement to other evidence-based practices — slow-paced breathing, regular exercise, quality sleep — not as a standalone treatment for any medical condition. If you have a diagnosed condition for which VNS has evidence (drug-resistant epilepsy, cluster headache, treatment-resistant depression), the conversation should be with your neurologist about prescription-grade devices, not a consumer purchase.

Contraindications and Safety

Vagus nerve stimulation — whether implantable, cervical, or auricular — is contraindicated in people with implanted cardiac devices (pacemakers, defibrillators) without explicit cardiology clearance, as electrical current near the vagus can theoretically affect cardiac rhythm. Carotid atherosclerosis, recent neck surgery, and active ear infections (for auricular devices) are additional precautions. Bilateral cervical VNS (stimulating both vagus nerves simultaneously) is avoided because of the risk of severe bradycardia or asystole. Consumer taVNS devices have a generally favourable safety profile in published studies, with the most common side effects being local tingling, skin irritation at the electrode site, and occasional headache.

Pregnant women should avoid VNS devices, as the effects of vagal stimulation on uterine contractility and foetal heart rate have not been adequately studied. Anyone taking medications that affect heart rate (beta-blockers, calcium channel blockers, digoxin) should consult their physician before using any VNS device.

Before investing in any device, invest in understanding the nerve itself — what it does, how it adapts, and which approaches have real evidence behind them. Get the Vagus Nerve & Me eBook for the complete picture.